Literature DB >> 9049201

Reduced p21(WAF1/CIP1) expression and p53 mutation in hepatocellular carcinomas.

A M Hui1, Y Kanai, M Sakamoto, H Tsuda, S Hirohashi.   

Abstract

p21(WAF1/CIP1) is a universal cyclin-dependent kinase (cdk) inhibitor, the expression of which is regulated by p53-dependent and p53-independent pathways. We examined p21(WAF1/CIP1) expression in and p53 status of 21 primary hepatocellular carcinomas (HCCs) by reverse-transcriptase polymerase chain reaction (RT-PCR) and by PCR single-strand conformation polymorphism (PCR-SSCP) analysis. p21(WAF1/CIP1) messenger RNA expression was reduced markedly in 8 of 21 HCCs (38.1%) and 5 of these 8 HCCs bore p53 mutations. The relative p21(WAF1/CIP1) messenger RNA expression value of HCCs with p53 mutations (.73 +/- .13 U, n = 6) was significantly lower than that of HCCs with wild-type p53 (1.00 +/- 0.21 U, n = 14; P < .01). The p21(WAF1/CIP1) expression levels in cancerous tissues (.73 +/- .13 U) were significantly reduced in comparison with those in noncancerous tissues (.97 +/- .13 U) (P < .01) in the 6 cases with p53 mutations. These data indicate that p21(WAF1/CIP1) expression in HCCs is predominantly regulated by dependence on p53 and that reduced p21(WAF1/CIP1 expression may participate in hepatocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9049201     DOI: 10.1002/hep.510250314

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  19 in total

1.  Anti-cancer effects of p21WAF1/CIP1 transcriptional activation induced by dsRNAs in human hepatocellular carcinoma cell lines.

Authors:  Zhi-ming Wu; Chun Dai; Ying Huang; Cui-fang Zheng; Qiong-zhu Dong; Guan Wang; Xiao-wen Li; Xiao-fei Zhang; Bin Li; Gang Chen
Journal:  Acta Pharmacol Sin       Date:  2011-06-13       Impact factor: 6.150

2.  Ephrin-A1 expression contributes to the malignant characteristics of {alpha}-fetoprotein producing hepatocellular carcinoma.

Authors:  H Iida; M Honda; H F Kawai; T Yamashita; Y Shirota; B-C Wang; H Miao; S Kaneko
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

3.  Inhibitory effect of tumor suppressor p33(ING1b) and its synergy with p53 gene in hepatocellular carcinoma.

Authors:  Zhi Zhu; Jing Lin; Jian-Hui Qu; Mark-A Feitelson; Can-Rong Ni; Fang-Mei Li; Ming-Hua Zhu
Journal:  World J Gastroenterol       Date:  2005-04-07       Impact factor: 5.742

4.  Effects of tachyplesin on proliferation and differentiation of human hepatocellular carcinoma SMMC-7721 cells.

Authors:  Gao-Liang Ouyang; Qi-Fu Li; Xuan-Xian Peng; Qing-Rong Liu; Shui-Gen Hong
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

5.  The effects of acute ethanol exposure on inhibitors of hepatic regenerative activity in the rat.

Authors:  M N Zhang; Y Gong; G Y Minuk
Journal:  Mol Cell Biochem       Date:  2000-04       Impact factor: 3.396

6.  Targeted p21WAF1/CIP1 activation by RNAa inhibits hepatocellular carcinoma cells.

Authors:  Mika Kosaka; Moo Rim Kang; Glen Yang; Long-Cheng Li
Journal:  Nucleic Acid Ther       Date:  2012-08-21       Impact factor: 5.486

Review 7.  Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy.

Authors:  Shogo Ohkoshi; Masahiko Yano; Yasunobu Matsuda
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

8.  Elucidation of susceptible factors to endoplasmic reticulum stress-mediated anticancer activity in human hepatocellular carcinoma.

Authors:  Po-Cheng Chiang; Jui-Ling Hsu; Ting-Chun Yeh; Shiow-Lin Pan; Jih-Hwa Guh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-29       Impact factor: 3.000

9.  Absence of p53 gene expression in selenium molecular prevention of chemically induced hepatocarcinogenesis in rats.

Authors:  Nasar Y Alwahaibi; Siti B Budin; Jamaludin H Mohamed
Journal:  Saudi J Gastroenterol       Date:  2011 Sep-Oct       Impact factor: 2.485

10.  p53 missense but not truncation mutations are associated with low levels of p21(CIP1/WAF1) mRNA expression in primary human sarcomas.

Authors:  S Mousses; N Gokgoz; J S Wunder; H Ozcelik; S Bull; R S Bell; I L Andrulis
Journal:  Br J Cancer       Date:  2001-06-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.